Decapeptyl SR approved for use in early puberty

The GnRH analogue Decapeptyl SR (triptorelin) has been approved for the treatment of precocious puberty starting before eight years of age in girls, and before nine years of age in boys.

The recommended dose is one intramuscular injection of Decapeptyl SR 11.25 mg every three months. Treatment should be stopped around the physiological age of puberty; for girls, a bone maturation age of more than 12 years; for boys, a bone maturation age of 13 to 14 years.

Further information: Ipsen Ltd, 190 Bath Road, Slough, Berkshire SL1 3XE. Tel: (01753) 627777.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic guidance for leg ulcer infection

New antibiotic guidance for leg ulcer infection

NICE has issued guidance on antibiotic choices and...

New insertion site for Nexplanon following safety concerns

New insertion site for Nexplanon following safety concerns

The MHRA has amended its advice relating to the long-acting...

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.

Beta blocker overdose warning for GPs

Beta blocker overdose warning for GPs

The toxicity of a commonly prescribed beta blocker...